3
Announcements
Trials
Browse
Landscape
Status
Terminated
2
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
30
Prostatic Neoplasms, Castration-Resistant
5
Neoplasm Metastasis
5
Breast Neoplasms
3
Prostate Carcinoma Metastatic to the Bone
2
Neoplasms
2
Hormone Refractory Prostate Cancer
2
Bone Metastatic Castration-resistant Prostate Cancer
2
Thyroid Neoplasms
1
Prostate Cancer Metastatic to Bone
1
Pain
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Lung Neoplasms
1
Fractures, Bone
1
Fatigue
1
Castration-resistant Prostate Cancer
1
Castrate-Resistant Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Bony Metastases From Castrate Refractory Prostate Cancer
1
Bone Neoplasms
1
Bone Metastases
1
Bone Diseases
1
Interventions
enzalutamide
2
radium Ra 223 dichloride
1
poly ICLC
1
olaparib
1
fluciclovine F-18
1
cabazitaxel
1
bempegaldesleukin
1
afuresertib
1
Radiosurgery
1
Radionuclide Imaging
1
Prednisone
1
Nivolumab
1
Docetaxel
1
Clinical Trials, Phase I as Topic
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Metastatic Castration-resistant Prostate Cancer
×
radium Ra 223 dichloride
×
Clear all
NCT02141438
2025-10-16
REASSURE
Bayer
Completed
1,472 enrolled
18 charts